Astra Zeneca Articles
AstraZeneca close to selling dental unit; fewer deaths with Brilinta in ACS patients than with clopidogrel
21 June 2011
AstraZeneca looses out on European Nexium-related patent decision; downgraded by BarCap
13 June 2011
AstraZeneca and Pozen sue Dr Reddy’s over Vimovo patent
27 April 2011
AstraZeneca ups 2011 forecast after UK and USA tax deals
28 March 2011
PDL BioPharma to pay MedImmune $92.5 million to resolve patent disputes; Mylan debuts generic Vfend
17 February 2011
Further cancer pipeline disappointment for AstraZeneca as zibotentan fails in Ph III
7 February 2011
New PDUFA date for AstraZeneca’s Brilinta in the USA
4 February 2011
AstraZeneca gets EU approval for Fluenz; provided $947 million drug savings for people in USA in 2010
1 February 2011
AstraZeneca's fostamatinib safe, but not effective, in RA patients unresponsive to biologic agents
31 January 2011
Strong Crestor sales boost AstraZeneca 2010 results
27 January 2011
AstraZeneca unit highlights potential for MEDI-573 as inhibitor of development and progression of cancer
21 January 2011
European Commission launches second monitoring purge of patent settlements in pharma sector
18 January 2011
US FDA delays AstraZeneca’s vandetanib NDA for three months; combo diabetes drug Kombiglyze launched
10 January 2011
AstraZeneca unit MedImmune in-licenses anti-inflammatory MAb from Amgen; latter’s Sensipar patent upheld
10 January 2011
USA’s FDA puts stops on Johnson & Johnson’s fulranumab and Regeneron/Sanofi-Aventis osteo drug due to side effect risks
4 January 2011
AstraZeneca takes $445 million charges as it pulls RSV drug candidate motavizumab as prophylactic
21 December 2010
AstraZeneca unit in 260 million-euro metabolic disease alliance with Evotec; disappointing Crestor patent ruling
16 December 2010
Generic erosion will constrain hospital-acquired infections drug market growth through 2019
14 December 2010
Aromatase inhibitors may increase risk of heart disease in postmenopausal women with breast cancer
10 December 2010
China Pharma completes of trials of rosuvastatin planning to commercialize generic Crestor in domestic market
7 December 2010
China and India set to become world leaders for innovation, says AstraZeneca public opinion survey
6 December 2010
US FDA advisory panel backs approval of AstraZeneca’s thyroid cancer drug vandetanib
3 December 2010
Par Pharma in deal with AstraZeneca for generic Accolate; J&J unit sues Mylan and Lupin over Prezista
24 November 2010
Bayer joins ranks of European drugmakers shedding jobs, and slashing costs; AstraZeneca confirms viewing Astra Tech options
19 November 2010
First-line use of Abilify more than doubles over past year for newly-diagnosed patients with bipolar disorder
19 November 2010
US Appeal Court backs preliminary injunction against Apotex over AstraZeneca’s Pulmicort Respules; rejects Eli Lilly’s Gemzar appeal
3 November 2010
Generic erosion of key high-priced brands will see acute coronary syndrome drug market fall 12% to $809 million in 2016
3 November 2010
AstraZeneca earns $100 million selling Nexium co-promotion rights in Japan to Daiichi Sankyo
1 November 2010
AstraZeneca sees 3rd-qtr 2010 earnings slump 27%, hit by charges and generic competition; sues Watson
28 October 2010
AstraZeneca in-licenses vaccine component; selects Alzheimer’s drug candidate from Astex accord; moves forward with BTG’s CytoFab
26 October 2010
Bristol-Myers Squibb’s R&D pipeline boosted by diabetes drug dapagliflozin, say Zacks analysts
18 October 2010
AstraZeneca gets EU backing for OA/RA drug Vimovo; Merck KGaA appeals EMEA decision on cladribine for MS
11 October 2010
Targacept slides as ADHD drug under development with AstraZeneca disappoints in Ph II
8 October 2010
Outcomes study to boost prospects for AstraZeneca’s Brilinta set to begin in fourth quarter
4 October 2010
AstraZeneca wins UK approval for Seroquel XL in major depression
29 September 2010
Pfizer calls a halt to Phase III study of Sutent in prostate cancer
28 September 2010
AstraZeneca prostate cancer drug fails in Phase III trial
28 September 2010
Positive CHMP opinions for AstraZeneca and Novartis, but suspension of Octapharma’s Octagam called for; Roche Avastin review
26 September 2010
US FDA and EMEA accepts AstraZeneca’s filing for vandetanib; SOBI gains orphan status for hemophilia A therapy in EU
23 September 2010
AstraZeneca/Rigel’s fostamatinib shows positive response in rheumatoid arthritis in Ph IIb study
22 September 2010
Positive new data on diabetes drugs from Novo Nordisk, AstraZeneca/B-MS and Sanofi-Aventis presented at EASD meeting
21 September 2010
US generics group GPhA encouraged with initial dialogue on FDA User Fees; AstraZeneca backs increased funding for the agency
21 September 2010
US FDA extends approval time for AstraZeneca’s Brilinta; OKs Savient’s Krystexxa, which could lead to sale of the firm
15 September 2010
AstraZeneca’s chief scientist views collaboration in the new era of drug discovery
15 September 2010
Strong data on AstraZeneca’s vandetanib in advanced papillary or follicular thyroid cancer; FDA clears new Faslodex dosage
13 September 2010
Silence Thera receives takeover approach from unnamed drug firm
7 September 2010
Tough road ahead for some generics after USA’s Federal Circuit Patent Use Code decisions
7 September 2010
AstraZeneca in deal with India’s Aurobindo to supply branded generics for emerging markets
6 September 2010
European approval for Merck & Co/Cardiome’s IV Brinavess; added use for AstraZeneca’s Seroquel recommended
2 September 2010
US FDA calls for additional trial of AstraZeneca/MedImmune’s RSV candidate motavizumab
31 August 2010
Highlights of ESC include strong data on AstraZeneca’s Brilinta and Servier’s Procoralan; ESC guideline for atrial fibrillation
31 August 2010
FDA's new safety controls for LABA-containing drugs will impact prescribing for the treatment of asthma
26 August 2010
AstraZeneca’s MedImmune unit in licensing deal with Phylogica for antimicrobial peptide
20 August 2010
Unipolar depression drug market set to decrease by nearly 10% in 2019 due to generic erosion
12 August 2010
Research briefs on Merck & Co’s boceprevir and Bayer’s Xarelto; legal updates from AstraZeneca and Daiichi Sankyo/Actavis
5 August 2010
New research shows that hospital stays are the main cost of bipolar disorder to UK’s NHS, accounting for 60% vs 7% for drugs
5 August 2010
US FDA advisory panel backs AstraZeneca’s Brilinta, as firm posts 22% rise in core EPS for 2nd-qtr 2010
29 July 2010
Product marketing briefs from Merck & Co, Merck Serono, GW/Almirall, AstraZeneca and Roche
28 July 2010
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
